Sun Pharma’s ILUMYA will get US FDA overview nod for psoriatic arthritis use
Sun Pharmaceutical Industries Limited mentioned on Monday, March 16, that the US Food and Drug Administration has accepted for overview a supplemental Biologics License Application (sBLA) for ILUMYA for the remedy of adults with energetic psoriatic arthritis. The FDA’s regulatory motion date for the applying is anticipated by October 29, 2026. “For many people living…